It's certainly not Alan holding them up! Would you hold up huge contracts that could add to the cash holdings in a significant way and get the ball rolling? These are slow moving, large contracts that aren't really the norm in the pharma industry, especially when exclusivity is being baked into negotiated prices etc. Also the length of contracts.
Remember what Alan said in the EC when discussing upcoming contracts and after talking to the nature of the AbbVie contract he followed with:
"Bear in mind that previously for Unifill we'd been paid $50m for exclusivity for a very narrow therapeutic class, and we're in a much stronger position now with a much broader range of 6 portfolio's of delivery systems with multiple platforms within each of those"
So is that us looking at getting over $50m in exclusivity/ufront/milestone payments from AbbVie as they are wanting exclusivity for the Finesse and Lisa Auto-Injector in the broad ranging Auto-Immune diseases. We will have to wait and see but I'd be thinking AbbVie will pay well north of $50m, maybe $80-$100m. Obviously this sort of deal will take a while to negotiate and if they were to want additional access to other devices/platforms - looking into the future for their pipeline drugs as well.
I'd expect to hear a few decent sized deals to come, at least, by this calendar year end with some new innovation/tech also
